HR 3433 118th Congress House Health Cancer Child health Congressional oversight Drug safety, medical device, and laboratory regulation Drug therapy Government studies and investigations Medical research Prescription drugs

Give Kids a Chance Act of 2024

Introduced: May 17, 2023 Introduced by: McCaul, Michael T. Republican · Texas See on congress.gov

Everywhere this bill has been 16 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Sep 24, 2024

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sep 23, 2024

Motion to reconsider laid on the table Agreed to without objection.

Sep 23, 2024

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)

Sep 23, 2024

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)

Sep 23, 2024

DEBATE - The House proceeded with forty minutes of debate on H.R. 3433.

Sep 23, 2024

Considered under suspension of the rules. (consideration: CR H5582-5587)

Sep 23, 2024

Mr. Bucshon moved to suspend the rules and pass the bill, as amended.

Sep 20, 2024

Placed on the Union Calendar, Calendar No. 594.

Sep 20, 2024

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.

Sep 18, 2024

Ordered to be Reported (Amended) by the Yeas and Nays: 43 - 0.

Sep 18, 2024

Committee Consideration and Mark-up Session Held

May 16, 2024

Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11.

May 16, 2024

Subcommittee Consideration and Mark-up Session Held

May 19, 2023

Referred to the Subcommittee on Health.

May 17, 2023

Referred to the House Committee on Energy and Commerce.

May 17, 2023

Introduced in House

Plain-English summary Congressional Research Service

Give Kids a Chance Act of 2023

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations so as to authorize investigations of new drugs that are used in combination with active ingredients that have already been approved and that (1) have been determined to be the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The Food and Drug Administration must issue guidance and report on the bill's implementation. The Government Accountability Office must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

What's happening now September 24, 2024

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees of jurisdiction 3